Evaxion Biotech A/S

NasdaqCM:EVAX Stock Report

Market Cap: US$23.8m

Evaxion Biotech Past Earnings Performance

Past criteria checks 0/6

Evaxion Biotech's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 14.5% annually.

Key information

-21.4%

Earnings growth rate

-8.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

No updates

Recent updates

Evaxion Biotech names Per Norlén as CEO

Oct 05

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Aug 10

Evaxion Biotech announces new CEO as Lars Wegner resigns

Aug 02

Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

Oct 27
Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Jun 29
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform

Jun 03

Revenue & Expenses Breakdown
Beta

How Evaxion Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:EVAX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-241114
30 Jun 230-251015
31 Mar 230-24916
31 Dec 220-23817
30 Sep 220-25719
30 Jun 220-24719
31 Mar 220-26720
31 Dec 210-25620
30 Sep 210-20616
30 Jun 210-19715
31 Mar 210-16612
31 Dec 200-15611
30 Sep 200-14511
31 Dec 190-1138

Quality Earnings: EVAX is currently unprofitable.

Growing Profit Margin: EVAX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EVAX is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.

Accelerating Growth: Unable to compare EVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: EVAX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.